Analysts Set REGENXBIO Inc. (NASDAQ:RGNX) Price Target at $35.27

Shares of REGENXBIO Inc. (NASDAQ:RGNX) have received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $35.27.

RGNX has been the subject of a number of analyst reports. Chardan Capital reiterated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a report on Wednesday, November 20th. Raymond James reiterated an “outperform” rating and set a $18.00 price target on shares of REGENXBIO in a research note on Thursday, October 10th. HC Wainwright lowered their price objective on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, November 21st. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a report on Friday, November 15th.

Insider Buying and Selling

In other news, Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.11, for a total transaction of $101,100.00. Following the completion of the sale, the director now owns 11,286 shares in the company, valued at $114,101.46. This trade represents a 46.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 13.13% of the stock is owned by insiders.

Institutional Trading of REGENXBIO

Several hedge funds have recently made changes to their positions in RGNX. Assenagon Asset Management S.A. lifted its holdings in REGENXBIO by 258.7% during the second quarter. Assenagon Asset Management S.A. now owns 816,384 shares of the biotechnology company’s stock valued at $9,552,000 after purchasing an additional 588,773 shares during the last quarter. Redmile Group LLC raised its position in shares of REGENXBIO by 7.1% in the third quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after purchasing an additional 323,100 shares during the period. Integral Health Asset Management LLC lifted its stake in shares of REGENXBIO by 25.0% during the 2nd quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock valued at $11,115,000 after buying an additional 190,000 shares in the last quarter. Millennium Management LLC boosted its holdings in REGENXBIO by 84.8% in the 2nd quarter. Millennium Management LLC now owns 306,487 shares of the biotechnology company’s stock worth $3,586,000 after buying an additional 140,666 shares during the period. Finally, Squarepoint Ops LLC grew its stake in REGENXBIO by 630.9% in the 2nd quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock valued at $1,711,000 after buying an additional 126,249 shares in the last quarter. 88.08% of the stock is currently owned by institutional investors.

REGENXBIO Trading Up 3.1 %

NASDAQ RGNX opened at $8.54 on Thursday. The company has a market cap of $423.11 million, a P/E ratio of -1.70 and a beta of 1.24. The company has a fifty day simple moving average of $9.72 and a 200 day simple moving average of $11.33. REGENXBIO has a 12-month low of $8.06 and a 12-month high of $28.80.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.